Heart failure with preserved ejection fraction

  • James D. Gladden
  • Wolfgang A. Linke
  • Margaret M. Redfield
Invited Review

Abstract

As part of this series devoted to heart failure (HF), we review the epidemiology, diagnosis, pathophysiology, and treatment of HF with preserved ejection fraction (HFpEF). Gaps in knowledge and needed future research are discussed.

Keywords

Heart failure Diastole 

References

  1. 1.
    Abudiab MM, Redfield MM, Melenovsky V, Olson TP, Kass DA, Johnson BD, Borlaug BA (2013) Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail 15:776–785PubMedGoogle Scholar
  2. 2.
    Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KFJ, Gheorghiade M (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group trial. Circulation 114:397–403PubMedCentralPubMedGoogle Scholar
  3. 3.
    Andersen MJ, Ersboll M, Axelsson A, Gustafsson F, Hassager C, Kober L, Borlaug BA, Boesgaard S, Skovgaard LT, Moller JE (2013) Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial. Circulation 127:1200–1208PubMedGoogle Scholar
  4. 4.
    Aronow WS, Ahn C, Kronzon I (1997) Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or =40 % treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 80:207–209PubMedGoogle Scholar
  5. 5.
    Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59:998–1005PubMedGoogle Scholar
  6. 6.
    Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260–269PubMedGoogle Scholar
  7. 7.
    Bishu K, Hamdani N, Kruger M, Mohammed SF, Ohtani T, Abdalrhim A, Ogut O, Burnett JC, Linke WA, Redfield MM (2010) cGMP enhancing therapy improves LV diastolic distensibility by phosphorylating titin. Circulation 122:A8754Google Scholar
  8. 8.
    Boilson BA, Schirger JA, Borlaug BA (2010) Caveat medicus! Pulmonary hypertension in the elderly: a word of caution. Eur J Heart Fail 12:89–93PubMedGoogle Scholar
  9. 9.
    Borbély A, van der Velden J, PAPP Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ (2005) Cardiomyocyte stiffness in diastolic heart failure. Circulation 111:774–781PubMedGoogle Scholar
  10. 10.
    Borbély A, Falcao-Pires I, van Heerebeek L et al (2009) Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 104:780–786PubMedGoogle Scholar
  11. 11.
    Borlaug BA, Kass DA (2008) Ventricular–vascular interaction in heart failure. Heart Fail Clin 4:23–36PubMedCentralPubMedGoogle Scholar
  12. 12.
    Borlaug BA, Paulus WJ (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32:670–679PubMedCentralPubMedGoogle Scholar
  13. 13.
    Borlaug BA, Redfield MM (2011) Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123:2006–2014PubMedCentralPubMedGoogle Scholar
  14. 14.
    Borlaug BA, Jaber WA, Ommen SR, Lam CS, Redfield MM, Nishimura RA (2011) Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 97:964–969PubMedCentralPubMedGoogle Scholar
  15. 15.
    Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM (2009) Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 54:410–418PubMedCentralPubMedGoogle Scholar
  16. 16.
    Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA (2006) Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114:2138–2147PubMedGoogle Scholar
  17. 17.
    Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM (2010) Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 3:588–595PubMedCentralPubMedGoogle Scholar
  18. 18.
    Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM (2010) Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 56:845–854PubMedCentralPubMedGoogle Scholar
  19. 19.
    Borlaug BA, Redfield MM, Melenovsky V, Kane GC, Karon BL, Jacobsen SJ, Rodeheffer RJ (2013) Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail 6:944–952PubMedGoogle Scholar
  20. 20.
    Borlaug BA, Sorajja P, Nishimura RA, Lam CSP, Redfield MM (2009) Do exercise hemodynamics enhance diagnosis of heart failure with preserved ejection fraction? Circulation 120:S756Google Scholar
  21. 21.
    Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH (2013) Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 34:1424–1431PubMedGoogle Scholar
  22. 22.
    Brubaker PH, Kitzman DW (2011) Chronotropic incompetence: causes, consequences, and management. Circulation 123:1010–1020PubMedCentralPubMedGoogle Scholar
  23. 23.
    Brubaker PH, Joo KC, Stewart KP, Fray B, Moore B, Kitzman DW (2006) Chronotropic incompetence and its contribution to exercise intolerance in older heart failure patients. J Cardiopulm Rehabil 26:86–89PubMedGoogle Scholar
  24. 24.
    Burchfield JS, Xie M, Hill JA (2013) Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 128:388–400PubMedGoogle Scholar
  25. 25.
    Burke MA, Katz DH, Beussink L et al (2013) Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. doi:10.1161/CIRCHEARTFAILURE.113.000854 PubMedGoogle Scholar
  26. 26.
    Burkhoff D, Mirsky I, Suga H (2005) Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 289:H501–H512PubMedGoogle Scholar
  27. 27.
    Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL (2006) Systolic and diastolic heart failure in the community. JAMA 296:2209–2216PubMedGoogle Scholar
  28. 28.
    Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ (2012) What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 60:2349–2356PubMedGoogle Scholar
  29. 29.
    Choudhury L, Gheorghiade M, Bonow RO (2002) Coronary artery disease in patients with heart failure and preserved systolic function. Am J Cardiol 89:719–722PubMedGoogle Scholar
  30. 30.
    Colin P, Ghaleh B, Hittinger L, Monnet X, Slama M, Giudicelli JF, Berdeaux A (2002) Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 282:H672–H679PubMedGoogle Scholar
  31. 31.
    Dauterman K, Pak PH, Maughan WL, Nussbacher A, Ariê S, Liu CP, Kass DA (1995) Contribution of external forces to left ventricular diastolic pressure. Implications for the clinical use of the Starling law. Ann Intern Med 122:737–742PubMedGoogle Scholar
  32. 32.
    De Keulenaer GW, Brutsaert DL (2011) Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation 123:1996–2004, discussion 2005PubMedGoogle Scholar
  33. 33.
    Deswal A, Richardson P, Bozkurt B, Mann DL (2011) Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 17:634–642PubMedGoogle Scholar
  34. 34.
    Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM (2012) Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 5:720–726PubMedCentralPubMedGoogle Scholar
  35. 35.
    Edelmann F, Stahrenberg R, Gelbrich G et al (2011) Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol 100:755–764PubMedCentralPubMedGoogle Scholar
  36. 36.
    Edelmann F, Wachter R, Schmidt AG et al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:781–791PubMedGoogle Scholar
  37. 37.
    Ennezat PV, Lefetz Y, Maréchaux S et al (2008) Left ventricular abnormal response during dynamic exercise in patients with heart failure and preserved left ventricular ejection fraction at rest. J Card Fail 14:475–480PubMedGoogle Scholar
  38. 38.
    Flather MD, Shibata MC, Coats AJ et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215–225PubMedGoogle Scholar
  39. 39.
    Freiburg A, Trombitas K, Hell W et al (2000) Series of exon-skipping events in the elastic spring region of titin as the structural basis for myofibrillar elastic diversity. Circ Res 86:1114–1121PubMedGoogle Scholar
  40. 40.
    Fukuda N, Wu Y, Nair P, Granzier HL (2005) Phosphorylation of titin modulates passive stiffness of cardiac muscle in a titin isoform-dependent manner. J Gen Physiol 125:257–271PubMedCentralPubMedGoogle Scholar
  41. 41.
    Fukuta H, Sane DC, Brucks S, Little WC (2005) Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112:357–363PubMedGoogle Scholar
  42. 42.
    Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, Little WC (2001) The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344:17–22PubMedGoogle Scholar
  43. 43.
    Gillebert TC, Leite-Moreira AF, De Hert SG (2000) Load dependent diastolic dysfunction in heart failure. Heart Fail Rev 5:345–355PubMedGoogle Scholar
  44. 44.
    Gradman AH, Wilson JT (2009) Hypertension and diastolic heart failure. Curr Cardiol Rep 11:422–429PubMedGoogle Scholar
  45. 45.
    Grutzner A, Garcia-Manyes S, Kotter S, Badilla CL, Fernandez JM, Linke WA (2009) Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J 97:825–834PubMedCentralPubMedGoogle Scholar
  46. 46.
    Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164–174PubMedGoogle Scholar
  47. 47.
    Guo W, Schafer S, Greaser ML et al (2012) RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med 18:766–773PubMedCentralPubMedGoogle Scholar
  48. 48.
    Ha JW, Chung N, Jang Y, Kang WC, Kang SM, Rim SJ, Shim WH, Cho SY, Kim SS (2000) Is the left atrial v. wave the determinant of peak pulmonary artery pressure in patients with pure mitral stenosis? Am J Cardiol 85:986–991PubMedGoogle Scholar
  49. 49.
    Hamdani N, Krysiak J, Kreusser MM, Neef S, Dos Remedios CG, Maier LS, Kruger M, Backs J, Linke WA (2013) Crucial role for Ca2(+)/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res 112:664–674PubMedGoogle Scholar
  50. 50.
    Hay I, Rich J, Ferber P, Burkhoff D, Maurer MS (2005) Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure. Am J Physiol Heart Circ Physiol 288:H1203–H1208PubMedGoogle Scholar
  51. 51.
    Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL (2008) Death in heart failure: a community perspective. Circ Heart Fail 1:91–97PubMedCentralPubMedGoogle Scholar
  52. 52.
    Herman DS, Lam L, Taylor MR et al (2012) Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366:619–628PubMedCentralPubMedGoogle Scholar
  53. 53.
    Hidalgo CG, Chung CS, Saripalli C, Methawasin M, Hutchinson KR, Tsaprailis G, Labeit S, Mattiazzi A, Granzier HL (2013) The multifunctional Ca(2+)/calmodulin-dependent protein kinase II delta (CaMKIIdelta) phosphorylates cardiac titin’s spring elements. J Mol Cell Cardiol 54:90–97PubMedCentralPubMedGoogle Scholar
  54. 54.
    Hidalgo C, Hudson B, Bogomolovas J, Zhu Y, Anderson B, Greaser M, Labeit S, Granzier H (2009) PKC phosphorylation of titin’s PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ Res 105:631–638PubMedCentralPubMedGoogle Scholar
  55. 55.
    Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW (2008) The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol 6:292–300PubMedGoogle Scholar
  56. 56.
    Hoit BD (2013) Left atrial size and function: role in prognosis. J Am Coll Cardiol. doi:10.1016/j.jacc.2013.10.055 Google Scholar
  57. 57.
    Hoshijima M, Ikeda Y, Iwanaga Y et al (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8:864–871PubMedGoogle Scholar
  58. 58.
    Hudson BD, Hidalgo CG, Gotthardt M, Granzier HL (2010) Excision of titin’s cardiac PEVK spring element abolishes PKCalpha-induced increases in myocardial stiffness. J Mol Cell Cardiol 48:972–978PubMedCentralPubMedGoogle Scholar
  59. 59.
    Hundley WG, Kitzman DW, Morgan TM, Hamilton CA, Darty SN, Stewart KP, Herrington DM, Link KM, Little WC (2001) Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 38:796–802PubMedGoogle Scholar
  60. 60.
    Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD (2014) Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res 114:266–282PubMedGoogle Scholar
  61. 61.
    Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H (2006) B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47:742–748PubMedGoogle Scholar
  62. 62.
    Jaber W, Maniu CV, Krysiak J, Shapiro BP, Meyer DM, Linke WA, Redfield MM (2008) Titin isoforms, extracellular matrix, and global chamber remodeling in experimental dilated cardiomyopathy: functional implications and mechanistic insights. Circ Heart Fail 1:192–199PubMedCentralPubMedGoogle Scholar
  63. 63.
    Jessup M, Greenberg B, Mancini D et al (2011) Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124:304–313PubMedGoogle Scholar
  64. 64.
    Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551PubMedGoogle Scholar
  65. 65.
    Kasner M, Westermann D, Lopez B, Gaub R, Escher F, Kuhl U, Schultheiss HP, Tschope C (2011) Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol 57:977–985PubMedGoogle Scholar
  66. 66.
    Kawaguchi M, Hay I, Fetics B, Kass DA (2003) Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107:714–720PubMedGoogle Scholar
  67. 67.
    Kaye DM, Hoshijima M, Chien KR (2008) Reversing advanced heart failure by targeting Ca2+ cycling. Annu Rev Med 59:13–28PubMedGoogle Scholar
  68. 68.
    Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP (2002) Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288:2144–2150PubMedGoogle Scholar
  69. 69.
    Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH (2013) Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 62:1330–1338PubMedGoogle Scholar
  70. 70.
    Kramer K, Kirkman P, Kitzman D, Little WC (2000) Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization. Am Heart J 140:451–455PubMedGoogle Scholar
  71. 71.
    Kranias EG, Hajjar RJ (2012) Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 110:1646–1660PubMedCentralPubMedGoogle Scholar
  72. 72.
    Kruger M, Linke WA (2006) Protein kinase-A phosphorylates titin in human heart muscle and reduces myofibrillar passive tension. J Muscle Res Cell Motil 27:435–444PubMedGoogle Scholar
  73. 73.
    Kruger M, Linke WA (2009) Titin-based mechanical signalling in normal and failing myocardium. J Mol Cell Cardiol 46:490–498PubMedGoogle Scholar
  74. 74.
    Kruger M, Linke WA (2011) The giant protein titin: a regulatory node that integrates myocyte signaling pathways. J Biol Chem 286:9905–9912PubMedCentralPubMedGoogle Scholar
  75. 75.
    Kruger M, Babicz K, von Frieling-Salewsky M, Linke WA (2010) Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy. J Mol Cell Cardiol 48:910–916PubMedGoogle Scholar
  76. 76.
    Kruger M, Sachse C, Zimmermann WH, Eschenhagen T, Klede S, Linke WA (2008) Thyroid hormone regulates developmental titin isoform transitions via the PI3K/AKT pathway. Circ Res 102:439–447PubMedGoogle Scholar
  77. 77.
    Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA (2009) Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 104:87–94PubMedGoogle Scholar
  78. 78.
    Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a “set up” for vascular disease. Circulation 107:139–146PubMedGoogle Scholar
  79. 79.
    Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107:346–354PubMedGoogle Scholar
  80. 80.
    Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53:1119–1126PubMedCentralPubMedGoogle Scholar
  81. 81.
    Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM (2007) Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115:1982–1990PubMedCentralPubMedGoogle Scholar
  82. 82.
    Lamas GA, Knight JD, Sweeney MO et al (2007) Impact of rate-modulated pacing on quality of life and exercise capacity—evidence from the Advanced Elements of Pacing Randomized Controlled Trial (ADEPT). Heart Rhythm 4:1125–1132PubMedGoogle Scholar
  83. 83.
    Linke WA, Bucker S (2012) King of hearts: a splicing factor rules cardiac proteins. Nat Med 18:660–661PubMedGoogle Scholar
  84. 84.
    Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, del Monte F, Hajjar RJ, Linke WA (2004) Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res 95:708–716PubMedGoogle Scholar
  85. 85.
    McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869PubMedGoogle Scholar
  86. 86.
    Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA (2007) Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 49:198–207PubMedGoogle Scholar
  87. 87.
    Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, Mozaffarian D (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108:1362–1370PubMedCentralPubMedGoogle Scholar
  88. 88.
    Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos JA, Redfield MM (2012) Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community based study. Circ Heart Fail 5:710–719PubMedCentralPubMedGoogle Scholar
  89. 89.
    Nagueh SF, Shah G, Wu Y, Torre-Amione G, King NM, Lahmers S, Witt CC, Becker K, Labeit S, Granzier HL (2004) Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation 110:155–162PubMedGoogle Scholar
  90. 90.
    Neagoe C, Kulke M, del Monte F, Gwathmey JK, de Tombe PP, Hajjar RJ, Linke WA (2002) Titin isoform switch in ischemic human heart disease. Circulation 106:1333–1341PubMedGoogle Scholar
  91. 91.
    Norman HS, Oujiri J, Larue SJ, Chapman CB, Margulies KB, Sweitzer NK (2011) Decreased cardiac functional reserve in heart failure with preserved systolic function. J Card Fail 17:301–308PubMedCentralPubMedGoogle Scholar
  92. 92.
    Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ (2000) Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 102:1788–1794PubMedGoogle Scholar
  93. 93.
    Owan TE, Redfield MM (2005) Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47:320–332PubMedGoogle Scholar
  94. 94.
    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259PubMedGoogle Scholar
  95. 95.
    Packer M (2011) Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. Circ Heart Fail 4:538–540PubMedGoogle Scholar
  96. 96.
    Paulus WJ, Tschope C (2013) A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62:263–271PubMedGoogle Scholar
  97. 97.
    Paulus WJ, Vantrimpont PJ, Shah AM (1994) Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans: assessment by bicoronary sodium nitroprusside infusion. Circulation 89:2070–2078PubMedGoogle Scholar
  98. 98.
    Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA (2006) Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest 116:1547–1560PubMedCentralPubMedGoogle Scholar
  99. 99.
    Phan TT, Abozguia K, Nallur Shivu G et al (2009) Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 54:402–409PubMedGoogle Scholar
  100. 100.
    Phan TT, Nallur Shivu G, Abozguia K, Davies C, Nassimizadeh M, Jimenez D, Weaver R, Ahmed I, Frenneaux M (2009) Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction. Circ Heart Fail 3:29–34PubMedGoogle Scholar
  101. 101.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717PubMedGoogle Scholar
  102. 102.
    Raskin A, Lange S, Banares K et al (2012) A novel mechanism involving four-and-a-half LIM domain protein-1 and extracellular signal-regulated kinase-2 regulates titin phosphorylation and mechanics. J Biol Chem 287:29273–29284PubMedCentralPubMedGoogle Scholar
  103. 103.
    Redfield MM, Borlaug BA, Lewis GD et al (2012) PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail 5:653–659PubMedCentralPubMedGoogle Scholar
  104. 104.
    Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268–1277PubMedGoogle Scholar
  105. 105.
    Redfield MM, Jacobsen SJ, Burnett JCJ, Mahoney DW, Bailey KR, Rodeheffer RJ (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289:194–202PubMedGoogle Scholar
  106. 106.
    Reil JC, Tardif JC, Ford I, Lloyd SM, O'Meara E, Komajda M, Borer JS, Tavazzi L, Swedberg K, Böhm M (2013) Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 62:1977–1985PubMedGoogle Scholar
  107. 107.
    Sakata S, Lebeche D, Sakata N et al (2007) Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts. Am J Physiol Heart Circ Physiol 292:H2356–H2363PubMedGoogle Scholar
  108. 108.
    Sasayama S, Nonogi H, Miyazaki S, Sakurai T, Kawai C, Eiho S, Kuwahara M (1985) Changes in diastolic properties of regional myocardium during pacing-induced ischemia in human subjects. J Am Coll Cardiol 5:599–606PubMedGoogle Scholar
  109. 109.
    Schmidt U, del Monte F, Miyamoto MH, Matsui T, Gwathmey JK, Rosenzweig A, Hajjar RJ (2000) Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation 101:790–796PubMedGoogle Scholar
  110. 110.
    Schultz JLJ, Glascock BJ, Witt SA, Nieman ML, Nattamai KJ, Liu LH, Lorenz JN, Shull GE, Kimball TR, Periasamy M (2004) Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am J Physiol Heart Circ Physiol 286:H1146–H1153Google Scholar
  111. 111.
    Schwammenthal E, Vered Z, Agranat O, Kaplinsky E, Rabinowitz B, Feinberg MS (2000) Impact of atrioventricular compliance on pulmonary artery pressure in mitral stenosis: an exercise echocardiographic study. Circulation 102:2378–2384PubMedGoogle Scholar
  112. 112.
    Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA (2012) Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 59:442–451PubMedGoogle Scholar
  113. 113.
    Shah RV, Desai AS, Givertz MM (2010) The effect of renin–angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail 16:260–267PubMedGoogle Scholar
  114. 114.
    Shah SJ, Gheorghiade M (2008) Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 300:431–433PubMedGoogle Scholar
  115. 115.
    Shapiro BP, Lam CS, Patel JB, Mohammed SF, Kruger M, Meyer DM, Linke WA, Redfield MM (2007) Acute and chronic ventricular-arterial coupling in systole and diastole: insights from an elderly hypertensive model. Hypertension 50:503–511PubMedGoogle Scholar
  116. 116.
    Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115:2108–2118PubMedCentralPubMedGoogle Scholar
  117. 117.
    Solomon SD, Janardhanan R, Verma A et al (2007) Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369:2079–2087PubMedGoogle Scholar
  118. 118.
    Solomon SD, Zile M, Pieske B et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380:1387–1395PubMedGoogle Scholar
  119. 119.
    Stehle R, Solzin J, Iorga B, Poggesi C (2009) Insights into the kinetics of Ca2+-regulated contraction and relaxation from myofibril studies. Pflugers Arch 458:337–357PubMedGoogle Scholar
  120. 120.
    Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC, Investigators GWTGSACA (2012) Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126:65–75PubMedGoogle Scholar
  121. 121.
    Taylor RS, Davies EJ, Dalal HM, Davis R, Doherty P, Cooper C, Holland DJ, Jolly K, Smart NA (2012) Effects of exercise training for heart failure with preserved ejection fraction: a systematic review and meta-analysis of comparative studies. Int J Cardiol 162:6–13PubMedGoogle Scholar
  122. 122.
    Tedford RJ, Hassoun PM, Mathai SC et al (2012) Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation 125:289–297PubMedCentralPubMedGoogle Scholar
  123. 123.
    van Heerebeek L, Borbély A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ (2006) Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113:1966–1973PubMedGoogle Scholar
  124. 124.
    van Heerebeek L, Hamdani N, Falcao-Pires I et al (2012) Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126:830–839PubMedGoogle Scholar
  125. 125.
    van Heerebeek L, Hamdani N, Handoko ML et al (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43–51PubMedGoogle Scholar
  126. 126.
    Van Tassell BW, Arena R, Biondi-Zoccai G et al (2014) Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART Pilot Study). Am J Cardiol 113:321–327PubMedGoogle Scholar
  127. 127.
    Verma A, Solomon SD (2009) Diastolic dysfunction as a link between hypertension and heart failure. Med Clin N Am 93:647–664PubMedGoogle Scholar
  128. 128.
    Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB (2012) Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 98:1763–1777PubMedGoogle Scholar
  129. 129.
    Westermann D, Lindner D, Kasner M et al (2011) Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4:44–52PubMedGoogle Scholar
  130. 130.
    Yamamoto K, Burnett JCJ, Redfield MM (1997) Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 273:H2406–H2414PubMedGoogle Scholar
  131. 131.
    Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:e240–e319PubMedGoogle Scholar
  132. 132.
    Zakeri R, Borlaug BA, McNulty S et al (2013) Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail 7:123–130PubMedGoogle Scholar
  133. 133.
    Zakeri R, Chamberlain AM, Roger VL, Redfield MM (2013) Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128:1085–1093PubMedGoogle Scholar
  134. 134.
    Zile MR, Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105:1503–1508PubMedGoogle Scholar
  135. 135.
    Zile MR, Baicu CF, Gaasch WH (2004) Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350:1953–1959PubMedGoogle Scholar
  136. 136.
    Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE (2011) Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124:2491–2501PubMedGoogle Scholar
  137. 137.
    Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ (2014) Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 114:101–108PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • James D. Gladden
    • 1
  • Wolfgang A. Linke
    • 2
  • Margaret M. Redfield
    • 1
  1. 1.Division of Cardiovascular Diseases, Department of MedicineMayo Clinic, Guggenheim 9Southwest RochesterUSA
  2. 2.Department of Cardiovascular PhysiologyRuhr University BochumBochumGermany

Personalised recommendations